MedTrace Logo

Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline

NCT00126516 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 395

Last updated 2013-10-30

No results posted yet for this study

Summary

The purpose of this study is to elucidate whether or not angiotensin II receptor blockers (ARB) are more beneficial or equal to angiotensin converting enzyme inhibitors (ACEI) on development or progression of silent brain infarction and cognitive decline in Japanese patients with essential hypertension in the elderly.

Conditions

Interventions

DRUG

Angiotensin II Receptor Antagonists

any dosage, frequency, and duration

DRUG

Angiotensin-converting Enzyme Inhibitors

any dosage, frequency, and duration

Sponsors & Collaborators

  • Nara Medical University

    lead OTHER

Principal Investigators

  • Yoshihiko Saito, MD, PhD · First Department of Internal Medicine, Nara Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00126516 on ClinicalTrials.gov